LGD-4033 (Ligandrol) | 120 x 5 mg

SAFETY DATA SHEET

LGD-4033 (Ligandrol) is a synthetic, non-steroidal Selective Androgen Receptor Modulator (SARM) under investigation for its high affinity and selectivity toward androgen receptors in skeletal muscle and bone tissue. It binds selectively to androgen receptors in skeletal muscle and bone tissue, with minimal interaction in non-target organs. Ligandrol has undergone Phase I clinical trials, where it demonstrated a favorable safety profile and dose-dependent increases in lean body mass, making it one of the most rigorously studied SARMs to date.

In research contexts, LGD-4033 has been shown to:

• Demonstrate dose-dependent augmentation of lean body mass in preclinical and early-phase clinical models, independent of resistance training stimuli.
• Enhance functional biomarkers associated with musculoskeletal performance in conditions simulating disuse, trauma, or catabolic imbalance.
• Contribute to the maintenance of bone mineral density and microarchitectural integrity in experimental models of osteopenia and age-related sarcopenia.
• Associated with transient and dose-dependent modulation of the hypothalamic–pituitary–gonadal axis, with minimal suppression observed at lower exposure levels.
• Exhibit high tissue selectivity with limited androgenic activity in non-target organs such as dermal tissue, hepatic cells, and prostate models.

Due to its high oral bioavailability and predictable pharmacokinetics, LGD-4033 is frequently used in research exploring muscle preservation, hormonal therapies, and aging-related decline.

⚠ Important Note: This product is supplied strictly for laboratory research use only. It is not approved for human consumption or therapeutic use. Not intended to diagnose, treat, cure, or prevent any disease.